公开(公告)号：US11124501B2

公开(公告)日：2021-09-21

申请号：US16212455

申请日：2018-12-06

Applicant: Cancer Research Technology Limited

Inventor： Keith Jones ,  Carl Rye ,  Nicola Chessum ,  Matthew Cheeseman ,  Adele E. Pasqua ,  Kurt G. Pike ,  Paul F. Faulder

IPC: C07D405/12 ,  C07D405/14 ,  C07D319/18 ,  C07D407/12 ,  C07D409/12 ,  C07D417/12 ,  C07D417/14 ,  C07D471/04 ,  C07D487/08 ,  C07D491/056 ,  A61K31/357 ,  A61K31/404 ,  A61K31/428 ,  A61K31/436 ,  A61P35/00

Abstract: The present invention relates to compounds of formula I as defined herein. The compounds of the present invention are inhibitors of heat shock factor 1 (HSF1). In particular, the present invention relates to the use of these compounds as therapeutic agents for the treatment and/or prevention of proliferative diseases, such as cancer. The present invention also relates to processes for the preparation of these compounds, and to pharmaceutical compositions comprising them.

公开(公告)号：US20210163497A1

公开(公告)日：2021-06-03

申请号：US17046650

申请日：2019-04-12

Applicant: Cancer Research Technology Limited ,  The Institute of Cancer Research: Royal Cancer Hospital

Inventor： Benjamin Richard Bellenie ,  Kwai Ming Jack Cheung ,  Owen Alexander Davis ,  Swen Hoelder ,  Rosemary Huckvale ,  Gavin Collie ,  Mirco Meniconi ,  Alfie Brennan ,  Matthew Garth Lloyd

IPC: C07D498/04 ,  C07D498/20 ,  C07D513/04 ,  C07D519/00 ,  C07D498/14 ,  C07D471/04 ,  A61P35/00

Abstract: The present invention relates to compounds of formula I that function as inhibitors of BCL6 (B-cell lymphoma 6) activity: wherein X1, X2, R1, R2, R30, R31 and Ring A are each as defined herein. The present invention also relates to processes for the preparation of these compounds, to pharmaceutical compositions comprising them, and to their use in the treatment of proliferative disorders, such as cancer, as well as other diseases or conditions in which BCL6 activity is implicated.

公开(公告)号：US11020396B2

公开(公告)日：2021-06-01

申请号：US16348073

申请日：2017-11-07

Applicant: Cancer Research Technology Limited

Inventor： Emma L. Carswell ,  Mark David Charles ,  Chukuemeka Tennyson Ekwuru ,  Frederic Elustondo ,  Katherine M. Fowler ,  Gregory R. Ott ,  Jonathan R. Roffey ,  Joanna L. Brookfield ,  Daniel James Ford ,  Mathew L. Calder

IPC: C07D403/14 ,  A61K31/506 ,  A61K31/437 ,  A61K31/551 ,  C07D413/14 ,  C07D417/14 ,  C07D471/04

Abstract: The present invention relates to compounds of formula I as defined herein, and salts and solvates thereof, that function as inhibitors of cell division cycle 7 (Cdc7) kinase enzyme activity. The present invention also relates to pharmaceutical compositions comprising them, and to their use in the treatment of proliferative disorders, such as cancer, as well as other diseases or conditions in which Cdc7 kinase activity is implicated.

公开(公告)号：US11001638B2

公开(公告)日：2021-05-11

申请号：US15773821

申请日：2016-11-04

Applicant: Cancer Research Technology Limited

Inventor： Aymen Al-Shamkhani ,  Hak Tak Claude Chan ,  Mark Steven Cragg ,  Ruth Rosemary French ,  Martin John Glennie ,  Jane Elizabeth Willoughby

IPC: C07K16/28 ,  A61K39/395 ,  A61P35/02 ,  A61K39/00 ,  A61K45/06

Abstract: The invention relates to antibodies specific for 4-1BB and OX40, as well as to methods for using such antibodies and therapeutic uses thereof.

公开(公告)号：US10981898B2

公开(公告)日：2021-04-20

申请号：US16535931

申请日：2019-08-08

Applicant: ASTEX THERAPEUTICS LIMITED ,  CANCER RESEARCH TECHNOLOGY LIMITED

Inventor： Gianni Chessari ,  Steven Howard ,  Ildiko Maria Buck ,  Benjamin David Cons ,  Christopher Norbert Johnson ,  Rhian Sara Holvey ,  David Charles Rees ,  Jeffrey David St. Denis ,  Emiliano Tamanini ,  Bernard Thomas Golding ,  Ian Robert Hardcastle ,  Celine Florence Cano ,  Duncan Charles Miller ,  Martin Edward Mäntylä Noble ,  Roger John Griffin ,  James Daniel Osborne ,  Joanne Peach ,  Arwel Lewis ,  Kim Louise Hirst ,  Benjamin Paul Whittaker ,  David Wyn Watson ,  Dale Robert Mitchell

IPC: C07D405/14 ,  C07D403/06 ,  C07D405/12 ,  C07D413/12 ,  C07D209/48 ,  C07D413/06 ,  C07D403/12 ,  C07F9/572 ,  A61P35/00

Abstract: The invention provides a compound of formula (I): or tautomer or a solvate or a pharmaceutically acceptable salt thereof, wherein the various substituents are as defined in the claims. Also provided are pharmaceutical compositions containing the compounds of formula (I), processes for making the compounds and the medical uses of the compounds.

公开(公告)号：US20210054084A1

公开(公告)日：2021-02-25

申请号：US16979933

申请日：2019-03-13

Applicant: Tusk Therapeutics Ltd. ,  Cancer Research Technology Limited

Inventor： Anne Goubier ,  Beatriz Goyenechea Corzo ,  Josephine Salimu ,  Kevin Moulder ,  Pascal Merchiers ,  Sergio Quezada

IPC: C07K16/28 ,  A61P35/00 ,  A61K39/395 ,  A61K45/06

Abstract: The present disclosure provides antibody sequences found in antibodies that bind to human CD25. In particular, the present disclosure provides sequences of anti-human CD25 antibodies, which do not block the binding of CD25 to IL-2 or IL-2 signalling. Antibodies and antigen-binding portions thereof including such sequences can be used in 5 pharmaceutical compositions and methods of treatment, in particular for treating cancer.

公开(公告)号：US20210047420A1

公开(公告)日：2021-02-18

申请号：US16979931

申请日：2019-03-13

Applicant: Tusk Therapeutics Ltd. ,  Cancer Research Technology Limited

Inventor： Anne Goubier ,  Beatriz Goyenechea Corzo ,  Josephine Salimu ,  Kevin Moulder ,  Pascal Merchiers ,  Sergio Quezada

IPC: C07K16/28 ,  A61K39/395 ,  A61K45/06 ,  A61P35/00

Abstract: The present disclosure provides antibody sequences found in antibodies that bind to human CD25. In particular, the present disclosure provides sequences of anti-human CD25 antibodies, which do not block the binding of CD25 to IL-2 or IL-2 signalling. Antibodies and antigen-binding portions thereof including such sequences can be used in pharmaceutical compositions and methods of treatment, in particular for treating cancer.

公开(公告)号：US10919973B2

公开(公告)日：2021-02-16

申请号：US16006119

申请日：2018-06-12

Applicant: Københavns Universitet ,  Cancer Research Technology Limited

Inventor： Henrik Clausen ,  Joy Burchell ,  Ulla Mandel ,  Anne Louise Sørensen ,  Mads Agervig Tarp ,  Joyce Taylor-Papadimitriou

IPC: C40B30/06 ,  C07K16/28 ,  A61K47/64 ,  A61K39/00 ,  C07K14/47 ,  C07K16/30 ,  G01N33/574 ,  G01N33/68 ,  C40B30/04 ,  C40B50/06

Abstract: The present invention provides a method for inducing a cancer specific immune response against MUC1 using an immunogenic glycopeptide. Other aspects of the invention are a pharmaceutical composition comprising the immunogenic glycopeptide and a cancer vaccine comprising the immunogenic glycopeptide. Another aspect is an antibody generated using the immunogenic glycopeptide and the use of said antibody in therapy and diagnosis.

公开(公告)号：US20210009704A1

公开(公告)日：2021-01-14

申请号：US16979935

申请日：2019-03-13

Applicant: Tusk Therapeutics Ltd. ,  Cancer Research Technology Limited

Inventor： Anne Goubier ,  Beatriz Goyenechea Corzo ,  Josephine Salimu ,  Kevin Moulder ,  Pascal Merchiers ,  Mark Brown ,  James Geoghegan ,  Bianka Prinz ,  Sergio Quezada

IPC: C07K16/28 ,  A61K39/395 ,  A61K45/06 ,  A61P35/00

Abstract: The present disclosure provides antibody sequences found in antibodies that bind to human CD25, in particular an anti CD25-a-674 antibody which do not block the binding of CD25 to IL-2 or IL-2 signalling. The claimed antibody binds to the epitopes: QCVQGYRA and RWTQPQLICTG on CD25 Antibodies and antigen-binding portions thereof including such sequences can be used in pharmaceutical compositions and methods of treatment, in particular for treating cancer.

公开(公告)号：US10654846B2

公开(公告)日：2020-05-19

申请号：US15548079

申请日：2016-02-04

Applicant: CANCER RESEARCH TECHNOLOGY LIMITED

Inventor： Martin Lee Stockley ,  Ellen Catherine MacDonald ,  Pritom Shah ,  Allan Jordan ,  James Hitchin ,  Niall Hamilton

IPC: A61K31/496 ,  A61K31/551 ,  A61K31/404 ,  A61K31/55 ,  A61K31/444 ,  A61K31/437 ,  A61K31/4184 ,  A61K31/4545 ,  A61K31/5025 ,  A61K31/5377 ,  A61K45/06 ,  C07D471/04 ,  C07D235/02

Abstract: The present invention relates to compounds of formula I, wherein A1, A2, A3, R1, R2, R3, R4, R5, R6, L, Ar and Q are each as defined herein. The compounds of the present invention are inhibitors of autotaxin (ATX) enzyme activity. The present invention also relates to processes for the preparation of these compounds, to pharmaceutical compositions comprising them, and to their use in the treatment of proliferative disorders, such as cancer, as well as other diseases or conditions (e.g. fibrosis) in which ATX activity is implicated.